New developments for antibody-drug conjugate-based therapeutic approaches (Q26766540)

https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008

7 January 2021

Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008

7 January 2021

Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008

7 January 2021

Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008

7 January 2021

Anti-CD30 Antibodies for Hodgkin lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008

7 January 2021

Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008

1 reference

7 January 2021

Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008

7 January 2021

Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008

7 January 2021

A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008

7 January 2021

Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody-Drug Conjugate SYD985.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008

7 January 2021

Efficacy of selected natural products as therapeutic agents against cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008

7 January 2021

Physiological parameters in laboratory animals and humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008

7 January 2021

Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008

7 January 2021

Cysteine cathepsins: multifunctional enzymes in cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008

7 January 2021

Microtubule-binding agents: a dynamic field of cancer therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008

7 January 2021

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008

7 January 2021

Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008

7 January 2021

Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008

7 January 2021

A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008

7 January 2021

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008

7 January 2021

Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008

7 January 2021

An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008

7 January 2021

A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008

7 January 2021

Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1).

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008

7 January 2021

First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008

7 January 2021

Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008

7 January 2021

High turnover of tissue factor enables efficient intracellular delivery of antibody-drug conjugates

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008

7 January 2021

The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008

7 January 2021

Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008

7 January 2021

MUC16 mucin is expressed by the human ocular surface epithelia and carries the H185 carbohydrate epitope

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008

7 January 2021

cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008

7 January 2021

Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008

7 January 2021

SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008

7 January 2021

Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008

7 January 2021

Head and neck cancer cells and xenografts are very sensitive to palytoxin: decrease of c-jun n-terminale kinase-3 expression enhances palytoxin toxicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008

7 January 2021

Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008

7 January 2021

Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008

7 January 2021

Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008

7 January 2021

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008

7 January 2021

Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008

7 January 2021

The development of pyrrolobenzodiazepines as antitumour agents

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008

7 January 2021

Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.02.008

7 January 2021